ES2383332T3 - Procedimiento de ligación de aceptores de péptidos - Google Patents
Procedimiento de ligación de aceptores de péptidos Download PDFInfo
- Publication number
- ES2383332T3 ES2383332T3 ES07005917T ES07005917T ES2383332T3 ES 2383332 T3 ES2383332 T3 ES 2383332T3 ES 07005917 T ES07005917 T ES 07005917T ES 07005917 T ES07005917 T ES 07005917T ES 2383332 T3 ES2383332 T3 ES 2383332T3
- Authority
- ES
- Spain
- Prior art keywords
- rna
- peptide acceptor
- linker
- rna molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 107
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 191
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 67
- 230000004927 fusion Effects 0.000 claims description 62
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical group C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 55
- 230000015572 biosynthetic process Effects 0.000 claims description 41
- 229950010131 puromycin Drugs 0.000 claims description 36
- 230000027455 binding Effects 0.000 claims description 33
- 238000004132 cross linking Methods 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000000524 functional group Chemical group 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- 150000008300 phosphoramidites Chemical class 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 108020005038 Terminator Codon Proteins 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 238000002788 crimping Methods 0.000 claims description 9
- 108091081024 Start codon Proteins 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 238000001261 affinity purification Methods 0.000 claims description 6
- 238000006268 reductive amination reaction Methods 0.000 claims description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 230000014621 translational initiation Effects 0.000 claims description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- SGAUPIBMJQWCEK-UHFFFAOYSA-N thionitrosourea Chemical compound NC(=O)NN=S SGAUPIBMJQWCEK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 11
- 239000000370 acceptor Substances 0.000 description 91
- 125000005647 linker group Chemical group 0.000 description 91
- 108020004999 messenger RNA Proteins 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 38
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 238000005755 formation reaction Methods 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 30
- 102000039446 nucleic acids Human genes 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 26
- 230000014616 translation Effects 0.000 description 21
- 238000013519 translation Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 238000011160 research Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 7
- -1 tyrosyl adenosine Chemical compound 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- KUVKCDXSFDLBDW-UHFFFAOYSA-N aminophosphonous acid;1,3-diaminourea Chemical compound NP(O)O.NNC(=O)NN KUVKCDXSFDLBDW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000002429 hydrazines Chemical class 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 150000007659 semicarbazones Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002352 Peptidyl-tRNA Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical group NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 150000003349 semicarbazides Chemical class 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- CTFJATOFOZBFPT-UCTKEYDRSA-N (2s)-2-amino-1-[(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-phenylpropan-1-one Chemical compound C([C@H](N)C(=O)[C@@]1([C@@H]([C@H](O)[C@@H](CO)O1)O)N1C2=NC=NC(N)=C2N=C1)C1=CC=CC=C1 CTFJATOFOZBFPT-UCTKEYDRSA-N 0.000 description 1
- BLOMDWFVDQMXKC-GFYCOGQESA-N (2s)-2-amino-1-[(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]propan-1-one Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C(=O)[C@@H](N)C)O[C@H](CO)[C@@H](O)[C@H]1O BLOMDWFVDQMXKC-GFYCOGQESA-N 0.000 description 1
- BSKFNPJZQAOQFD-SIUDKIQTSA-N (2s)-2-amino-1-[(2s,3r,4s,5s)-4-amino-2-(6-aminopurin-9-yl)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-phenylpropan-1-one Chemical compound C([C@H](N)C(=O)[C@@]1([C@@H]([C@H](N)[C@@H](CO)O1)O)N1C2=NC=NC(N)=C2N=C1)C1=CC=CC=C1 BSKFNPJZQAOQFD-SIUDKIQTSA-N 0.000 description 1
- VLUUFBLAENSMJV-AEKHSPFPSA-N (2s)-2-amino-1-[(2s,3r,4s,5s)-4-amino-2-(6-aminopurin-9-yl)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]propan-1-one Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C(=O)[C@@H](N)C)O[C@H](CO)[C@@H](N)[C@H]1O VLUUFBLAENSMJV-AEKHSPFPSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- CJHGCXGTUHBMMH-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl dihydrogen phosphate Chemical compound OCCOCCOCCOP(O)(O)=O CJHGCXGTUHBMMH-UHFFFAOYSA-N 0.000 description 1
- DRESTDPDCGPKNI-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(2-nitrophenyl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(CC(=O)O)C1=CC=CC=C1[N+]([O-])=O DRESTDPDCGPKNI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KYVGPEJZDJMZCA-KFZUYFRSSA-N 4-amino-1-[(2r,3r,4r,5r)-3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 KYVGPEJZDJMZCA-KFZUYFRSSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000005351 kimble Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Chemical group 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Chemical group 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14583499P | 1999-07-27 | 1999-07-27 | |
| US145834P | 1999-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2383332T3 true ES2383332T3 (es) | 2012-06-20 |
Family
ID=22514769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07005917T Expired - Lifetime ES2383332T3 (es) | 1999-07-27 | 2000-07-19 | Procedimiento de ligación de aceptores de péptidos |
| ES00947524T Expired - Lifetime ES2284508T3 (es) | 1999-07-27 | 2000-07-19 | Procedimientos de ligadura de aceptador de peptidos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00947524T Expired - Lifetime ES2284508T3 (es) | 1999-07-27 | 2000-07-19 | Procedimientos de ligadura de aceptador de peptidos. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6429300B1 (enExample) |
| EP (2) | EP1196637B1 (enExample) |
| JP (2) | JP4766808B2 (enExample) |
| KR (1) | KR20020033743A (enExample) |
| AT (2) | ATE360706T1 (enExample) |
| AU (2) | AU781783B2 (enExample) |
| CA (2) | CA2377468C (enExample) |
| CY (1) | CY1113185T1 (enExample) |
| DE (1) | DE60034566T2 (enExample) |
| DK (2) | DK1196637T3 (enExample) |
| ES (2) | ES2383332T3 (enExample) |
| HK (1) | HK1045334A1 (enExample) |
| IL (1) | IL147037A0 (enExample) |
| NO (1) | NO20020348L (enExample) |
| PT (2) | PT1196637E (enExample) |
| WO (1) | WO2001007657A1 (enExample) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1045334A1 (zh) * | 1999-07-27 | 2002-11-22 | Phylos, Inc. | 缩氨酸受体结紮方法 |
| US7186813B1 (en) | 2000-01-11 | 2007-03-06 | Nanogen Recognomics Gmbh | Biomolecules having multiple attachment moieties for binding to a substrate surface |
| JP2003530094A (ja) * | 2000-03-31 | 2003-10-14 | メモレック シュトッフェル ゲゼルシャフト ミット ベシュレンクテル ハフツング メディツィニッシューモレクラー エントヴィクルンク，ケルン | 核酸の抽出方法 |
| US7410761B2 (en) * | 2000-05-19 | 2008-08-12 | Proteonova, Inc. | System for rapid identification and selection of nucleic acids and polypeptides, and method thereof |
| WO2003044194A1 (en) * | 2001-11-16 | 2003-05-30 | Proteonova, Inc. | Selection and evolution of nucleic acids and polypeptides |
| US20040229271A1 (en) * | 2000-05-19 | 2004-11-18 | Williams Richard B. | Compositions and methods for the identification and selection of nucleic acids and polypeptides |
| US6962781B1 (en) * | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
| US7129229B2 (en) | 2000-08-11 | 2006-10-31 | Nanogen Recognomics Gmbh | Hydrazide building blocks and hydrazide modified biomolecules |
| JP4880182B2 (ja) * | 2000-08-11 | 2012-02-22 | ナノジェン・レコグノミクス・ゲーエムベーハー | ヒドラジド結合部分を有する巨大分子およびそれらの製造用試剤 |
| JP4963142B2 (ja) * | 2000-12-14 | 2012-06-27 | 学校法人慶應義塾 | 遺伝子型と表現型の対応付け分子とその構成要素、および対応付け分子の製造方法と利用方法 |
| US20060234231A1 (en) * | 2001-06-20 | 2006-10-19 | Nuevolution A/S | Microarrays displaying encoded molecules |
| EP1401850A1 (en) | 2001-06-20 | 2004-03-31 | Nuevolution A/S | Nucleoside derivatives for library preparation |
| US6893822B2 (en) | 2001-07-19 | 2005-05-17 | Nanogen Recognomics Gmbh | Enzymatic modification of a nucleic acid-synthetic binding unit conjugate |
| EP1419274A4 (en) * | 2001-07-31 | 2006-02-08 | Phylos Inc | MODULAR CONSTRUCTION OF NUCLEIC ACID PROTEIN FUSION MULTIMERS |
| DE10147074A1 (de) * | 2001-09-25 | 2003-05-08 | Beru Ag | Verfahren zum Betreiben einer aus mehreren Heizelementen bestehenden mehrstufigen elektrischen Heizung |
| AU2002365404A1 (en) | 2001-11-27 | 2003-06-10 | Compound Therapeutics, Inc. | Solid-phase immobilization of proteins and peptides |
| DE20200926U1 (de) * | 2002-01-23 | 2002-04-18 | Hegenscheidt-MFD GmbH & Co. KG, 41812 Erkelenz | Festwalzgerät einer Festwalzmaschine für Kurbelwellen |
| WO2003078627A2 (en) * | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block capable of functional entity transfer to nucleophil |
| WO2003078446A2 (en) * | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block forming a c-c or a c-hetero atom bond upon reaction |
| WO2003078050A2 (en) * | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block forming a c-c bond upon reaction |
| US7413854B2 (en) * | 2002-03-15 | 2008-08-19 | Nuevolution A/S | Method for synthesising templated molecules |
| US10730906B2 (en) * | 2002-08-01 | 2020-08-04 | Nuevolutions A/S | Multi-step synthesis of templated molecules |
| AU2003256857A1 (en) * | 2002-08-08 | 2004-02-25 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
| EP1558744B1 (en) | 2002-10-30 | 2011-06-15 | Nuevolution A/S | Enzymatic encoding |
| WO2004056994A2 (en) | 2002-12-19 | 2004-07-08 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
| EP1597394A2 (en) * | 2003-02-21 | 2005-11-23 | Nuevolution A/S | A method for obtaining structural information about an encoded molecule |
| US20070026397A1 (en) * | 2003-02-21 | 2007-02-01 | Nuevolution A/S | Method for producing second-generation library |
| EP2236606B1 (en) * | 2003-03-20 | 2013-11-06 | Nuevolution A/S | Ligational encoding of small molecules |
| WO2004110964A2 (en) * | 2003-06-16 | 2004-12-23 | Nuevolution A/S | Encoded molecules by translation (emt) |
| US20050095627A1 (en) * | 2003-09-03 | 2005-05-05 | The Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
| EP1670939B1 (en) * | 2003-09-18 | 2009-11-04 | Nuevolution A/S | A method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
| EP1692313A2 (en) * | 2003-11-20 | 2006-08-23 | Sanofi Pasteur Inc. | Methods for purifying pertussis toxin and peptides useful therefor |
| SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
| AU2004314705A1 (en) * | 2003-12-12 | 2005-08-11 | Proteonova, Inc. | System and methods for nucleic acid and polypeptide selection |
| WO2005078122A2 (en) * | 2004-02-17 | 2005-08-25 | Nuevolution A/S | Method for enrichment involving elimination by mismatch hybridisation |
| DK1730277T3 (da) * | 2004-03-22 | 2010-03-01 | Nuevolution As | Kodning ved ligering under anvendelse af byggebloksoligonukleotider |
| CA2467321A1 (en) * | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
| WO2006041194A1 (ja) | 2004-10-15 | 2006-04-20 | Japan Science And Technology Agency | ｍＲＮＡ－ピューロマイシン－タンパク質連結体作製用リンカー |
| EP1846432A4 (en) | 2005-01-12 | 2008-11-19 | Proteonova Inc | METHOD FOR MANUFACTURING TARGETED THERAPEUTIC AGENTS |
| US10206998B2 (en) | 2005-01-12 | 2019-02-19 | Proteonova, Inc. | Modular targeted therapeutic agents and methods of making same |
| EP2339014B1 (en) | 2005-11-16 | 2015-05-27 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| EP2341140B1 (en) | 2005-12-01 | 2017-07-19 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
| US7749957B2 (en) | 2006-04-06 | 2010-07-06 | E.I. Du Pont De Nemours And Company | Clay-binding peptides and methods of use |
| JP5537946B2 (ja) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬 |
| CA2677804C (en) | 2007-02-12 | 2017-03-14 | Proteonova, Inc. | Generation of library of soluble random polypeptides linked to mrna |
| US7678883B2 (en) | 2007-07-25 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Solubility tags for the expression and purification of bioactive peptides |
| US7951559B2 (en) * | 2007-07-25 | 2011-05-31 | E.I. Du Pont De Nemours And Company | Recombinant peptide production using a cross-linkable solubility tag |
| US7829311B2 (en) | 2007-07-25 | 2010-11-09 | E.I. Du Pont De Nemours And Company | Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate |
| US7794963B2 (en) | 2007-11-02 | 2010-09-14 | E.I. Du Pont De Nemours And Company | Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| KR20150080038A (ko) | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| AU2009213141A1 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
| JP5774474B2 (ja) * | 2008-05-02 | 2015-09-09 | エピセンター テクノロジーズ コーポレーションＥｐｉｃｅｎｔｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｒｎａへの選択的な５’ライゲーションによるタグの付加 |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| KR20110036638A (ko) | 2008-07-25 | 2011-04-07 | 리차드 더블유. 와그너 | 단백질 스크리닝 방법 |
| CA2737035A1 (en) * | 2008-09-30 | 2010-04-08 | Abbott Laboratories | Improved method of rna display |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US8287845B2 (en) * | 2008-12-18 | 2012-10-16 | E I Du Pont De Nemours And Company | Hair-binding peptides |
| US20100158822A1 (en) * | 2008-12-18 | 2010-06-24 | E .I. Du Pont De Nemours And Company | Peptides that bind to silica-coated particles |
| US20100158837A1 (en) | 2008-12-18 | 2010-06-24 | E. I. Du Pont De Nemours And Company | Iron oxide-binding peptides |
| US20100158846A1 (en) * | 2008-12-18 | 2010-06-24 | E. I. Du Pont De Nemours And Company | Hair-binding peptides |
| US8481678B2 (en) | 2009-03-30 | 2013-07-09 | E I Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
| EP2414045A2 (en) * | 2009-03-30 | 2012-02-08 | Johnson & Johnson | Peptide-based systems for delivery of costmetic agents |
| JP5733784B2 (ja) * | 2009-09-24 | 2015-06-10 | 国立大学法人埼玉大学 | ｃＤＮＡ／ｍＲＮＡ−タンパク質連結体の効率的合成法 |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| JP2013519869A (ja) | 2010-02-10 | 2013-05-30 | ノバルティス アーゲー | 筋肉成長のための方法および化合物 |
| HUE030724T2 (en) * | 2010-04-09 | 2017-06-28 | Univ Utrecht Holding Bv | Recombinant multimer influenza proteins |
| US11225655B2 (en) | 2010-04-16 | 2022-01-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| ES2573108T3 (es) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| EP3222631A3 (en) | 2010-07-30 | 2017-11-22 | Novartis AG | Fibronectin cradle molecules and libraries thereof |
| DE102010056289A1 (de) | 2010-12-24 | 2012-06-28 | Geneart Ag | Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken |
| WO2012125733A2 (en) | 2011-03-15 | 2012-09-20 | X-Body, Inc. | Antibody screening methods |
| SG194233A1 (en) | 2011-04-28 | 2013-12-30 | Univ Leland Stanford Junior | Identification of polynucleotides associated with a sample |
| EP2742153B1 (en) | 2011-08-01 | 2018-09-05 | The General Hospital Corporation | Protein and peptide libraries |
| WO2013055745A2 (en) | 2011-10-11 | 2013-04-18 | Medimmune, Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| US9416179B2 (en) | 2011-12-05 | 2016-08-16 | X-Body, Inc. | PDGF receptor beta binding polypeptides |
| EP2975121A4 (en) * | 2013-03-13 | 2016-07-20 | Univ Tokyo | NUCLEIC LEFT |
| KR102309517B1 (ko) | 2013-06-28 | 2021-10-07 | 엑스-바디 인코포레이티드 | 표적 항원 발견, 표현형 선별 및 표적 세포 특이성 표적 에피토프를 규명하기 위한 그의 용도 |
| CN103382579B (zh) * | 2013-07-06 | 2015-10-21 | 中国科学院成都生物研究所 | 一种体外筛选多肽的方法 |
| EP3049811B1 (en) | 2013-09-23 | 2020-09-09 | X-Body, Inc. | Methods and compositions for generation of binding agents against cell surface antigens |
| US20150184214A1 (en) * | 2013-12-31 | 2015-07-02 | Roche Nimblegen, Inc. | Enrichment of full length oligonucleotides via transcription/translation mediated purification |
| US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| EA202090216A3 (ru) | 2014-03-20 | 2020-07-31 | Бристол-Майерс Сквибб Компани | Связывающие сывороточный альбумин домены фибронектина iii типа |
| JP6478392B2 (ja) * | 2014-12-26 | 2019-03-06 | 国立研究開発法人産業技術総合研究所 | 核酸リンカー |
| KR20240093725A (ko) | 2015-03-12 | 2024-06-24 | 메디뮨 엘엘씨 | 알부민 융합 단백질의 정제 방법 |
| EP3708580B1 (en) | 2015-09-23 | 2023-11-01 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| KR102379048B1 (ko) | 2016-05-02 | 2022-03-28 | 엔코디아, 인코포레이티드 | 암호화 핵산을 사용한 거대분자 분석 |
| US11713482B2 (en) | 2016-06-15 | 2023-08-01 | Genecapture, Inc. | Compositions, methods and devices comprising stem-loop captor molecules |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| WO2018174078A1 (ja) | 2017-03-21 | 2018-09-27 | 富士フイルム株式会社 | ペプチド化合物およびその製造方法、スクリーニング用組成物、並びにペプチド化合物の選択方法 |
| CA3081441C (en) | 2017-10-31 | 2023-08-29 | Encodia, Inc. | Kits for analysis using nucleic acid encoding and/or label |
| MX2020003695A (es) | 2017-11-30 | 2020-08-03 | Arrakis Therapeutics Inc | Fotosondas de union a acido nucleico y usos de las mismas. |
| US20210113457A1 (en) | 2018-02-02 | 2021-04-22 | Ripple Therapeutics Corporation | Glass formulations and uses thereof |
| TWI830718B (zh) * | 2018-02-09 | 2024-02-01 | 日商住友化學股份有限公司 | 核酸分子之製造方法 |
| EP3778914A4 (en) * | 2018-03-30 | 2022-01-19 | Sumitomo Chemical Company, Ltd. | Method for producing single-strand rna |
| WO2019236644A1 (en) * | 2018-06-05 | 2019-12-12 | Arrakis Therapeutics, Inc. | Encoded libraries and methods of use for screening nucleic acid targets |
| US12473326B2 (en) | 2019-02-01 | 2025-11-18 | Ripple Therapeutics Corporation | Crystalline forms of dexamethasone dimers and uses thereof |
| CN115956083A (zh) | 2020-05-01 | 2023-04-11 | 波纹疗法公司 | 异二聚体组合物及用于治疗眼部病症的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361943B1 (en) * | 1996-10-17 | 2002-03-26 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
| US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| AU8124694A (en) * | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| DE19646372C1 (de) * | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
| ATE199572T1 (de) * | 1995-11-21 | 2001-03-15 | Univ Yale | Unimolekulare segmentamplifikation und bestimmung |
| US6117635A (en) * | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US5842701A (en) * | 1996-10-08 | 1998-12-01 | Smith International, Inc. | Dual functioning seal for rock bits |
| WO1998015636A1 (en) | 1996-10-10 | 1998-04-16 | Henrik Garoff | Alphavirus-retrovirus vectors |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| KR100566859B1 (ko) | 1997-01-21 | 2006-04-03 | 제너럴 하스피톨 코포레이션 | Ｒｎａ-단백질 융합물을 이용한 단백질의 선별 |
| US5935791A (en) * | 1997-09-23 | 1999-08-10 | Becton, Dickinson And Company | Detection of nucleic acids by fluorescence quenching |
| DK1052292T3 (da) * | 1997-12-22 | 2003-07-28 | Genset Sa | Prostatacancer-gen |
| US5985575A (en) * | 1998-05-20 | 1999-11-16 | Wisconsin Alumni Research Foundation | Tethered function assay for protein function |
| HK1045334A1 (zh) * | 1999-07-27 | 2002-11-22 | Phylos, Inc. | 缩氨酸受体结紮方法 |
| CA2382545C (en) * | 1999-08-27 | 2013-08-13 | Phylos, Inc. | Methods for encoding and sorting in vitro translated proteins |
-
2000
- 2000-07-19 HK HK02106728.4A patent/HK1045334A1/zh unknown
- 2000-07-19 AU AU61112/00A patent/AU781783B2/en not_active Expired
- 2000-07-19 PT PT00947524T patent/PT1196637E/pt unknown
- 2000-07-19 DK DK00947524T patent/DK1196637T3/da active
- 2000-07-19 EP EP00947524A patent/EP1196637B1/en not_active Expired - Lifetime
- 2000-07-19 ES ES07005917T patent/ES2383332T3/es not_active Expired - Lifetime
- 2000-07-19 AT AT00947524T patent/ATE360706T1/de active
- 2000-07-19 PT PT07005917T patent/PT1870417E/pt unknown
- 2000-07-19 ES ES00947524T patent/ES2284508T3/es not_active Expired - Lifetime
- 2000-07-19 IL IL14703700A patent/IL147037A0/xx unknown
- 2000-07-19 KR KR1020027001058A patent/KR20020033743A/ko not_active Withdrawn
- 2000-07-19 CA CA2377468A patent/CA2377468C/en not_active Expired - Lifetime
- 2000-07-19 EP EP07005917A patent/EP1870417B9/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,103 patent/US6429300B1/en not_active Expired - Lifetime
- 2000-07-19 DK DK07005917.5T patent/DK1870417T3/da active
- 2000-07-19 WO PCT/US2000/019653 patent/WO2001007657A1/en not_active Ceased
- 2000-07-19 DE DE60034566T patent/DE60034566T2/de not_active Expired - Lifetime
- 2000-07-19 CA CA2693274A patent/CA2693274C/en not_active Expired - Lifetime
- 2000-07-19 AT AT07005917T patent/ATE551352T1/de active
- 2000-07-19 JP JP2001512922A patent/JP4766808B2/ja not_active Expired - Lifetime
-
2002
- 2002-01-23 NO NO20020348A patent/NO20020348L/no not_active Application Discontinuation
- 2002-07-30 US US10/208,357 patent/US7078197B2/en not_active Expired - Lifetime
-
2005
- 2005-09-15 AU AU2005211548A patent/AU2005211548B2/en not_active Expired
-
2006
- 2006-07-10 US US11/483,495 patent/US7790421B2/en not_active Expired - Fee Related
-
2010
- 2010-08-24 JP JP2010186725A patent/JP5512463B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-08 CY CY20121100522T patent/CY1113185T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2383332T3 (es) | Procedimiento de ligación de aceptores de péptidos | |
| US6312927B1 (en) | Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation | |
| JP5174971B2 (ja) | ペプチド翻訳合成におけるｒａｐｉｄディスプレイ法 | |
| ES2280131T3 (es) | Fusiones de adn-proteina y utilizaciones de las mismas. | |
| ES2960381T3 (es) | Expresión acelular de proteínas utilizando ADN concatemérico bicatenario | |
| WO2003062417A1 (fr) | Produit de ligation arn-adn, et utilisation correspondante | |
| JP2004097213A (ja) | 核酸および／またはタンパク質の選択方法 | |
| JPWO2005024018A1 (ja) | 核酸構築物およびその製造方法 | |
| JP4745577B2 (ja) | アミノアシル化活性を有した触媒ＲＮＡｓ | |
| AU2008200974B2 (en) | Peptide acceptor ligation methods | |
| WO2016134521A1 (en) | Dna display and methods thereof | |
| HK1112007B (en) | Peptide acceptor ligation methods | |
| JP2003299489A (ja) | 核酸構築物 |